Repligen (NASDAQ:RGEN – Get Free Report) and Abpro (NASDAQ:ABP – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
Earnings and Valuation
This table compares Repligen and Abpro”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Repligen | $634.44 million | 14.40 | -$25.51 million | $0.02 | 8,116.50 |
| Abpro | $180,000.00 | 39.44 | -$7.23 million | ($4.23) | -0.62 |
Insider & Institutional Ownership
97.6% of Repligen shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 1.2% of Repligen shares are held by insiders. Comparatively, 13.7% of Abpro shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Repligen has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Abpro has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Repligen and Abpro, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Repligen | 0 | 3 | 11 | 1 | 2.87 |
| Abpro | 1 | 1 | 0 | 0 | 1.50 |
Repligen presently has a consensus price target of $179.62, suggesting a potential upside of 10.65%. Abpro has a consensus price target of $120.00, suggesting a potential upside of 4,497.70%. Given Abpro’s higher possible upside, analysts plainly believe Abpro is more favorable than Repligen.
Profitability
This table compares Repligen and Abpro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Repligen | 0.25% | 4.66% | 3.28% |
| Abpro | N/A | N/A | -344.76% |
Summary
Repligen beats Abpro on 11 of the 15 factors compared between the two stocks.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
About Abpro
Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
